Actinium Pharmaceuticals, Inc.
501 Fifth Avenue
New York City
New York
10017
United States
Tel: 646-459-4201
358 articles about Actinium Pharmaceuticals, Inc.
-
Actinium Pharmaceuticals Announces Multiple Posters/Abstracts Accepted for 59th Annual American Society of Hematology Meeting Highlighting Company’s Drug Candidates and Technology Platform
11/1/2017
A poster presentation will highlight data from Actinium’s Phase 2 trial of Actimab-A in patients newly diagnosed with acute myeloid leukemia.
-
Actinium Pharmaceuticals Announces Activation of Fifteenth Clinical Trial Site in the Phase III S...
10/25/2017
Actinium to provide update on SIERRA clinical trial by year-end. -
Actinium Provides Update On Actimab-A Phase II Clinical Trial For Patients With Acute Myeloid Leukemia
10/4/2017
-
Actinium Announces Closing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock
8/3/2017
-
Actinium Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Stock
7/28/2017
-
Actinium Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock
7/28/2017
-
Actinium To Host Webinar Focused On Actimab-A And Recent Developments Related To CD33 Targeted AML Therapies On July 13, 2017 At 8:00 Am ET
7/13/2017
-
Actinium To Host Webinar Focused On Actimab-A And Recent Developments Related To CD33 Targeted AML Therapies On July 13, 2017 At 8:00 Am ET
7/6/2017
-
Actinium Issues Mid-Year Letter To Shareholders Highlighting Accomplishments And Significant Value Enumerating Catalysts Over The Coming Quarters
6/15/2017
-
Actinium Announces Appointment Of Nitya Ray, Ph.D. As Executive Vice-President, Head Of Product Development, Manufacturing And Supply Chain And Other Key Hires In Its Product Development And Manufacturing Teams
6/15/2017
-
Actinium To Host Webinar On June 12th To Update On Pivotal Phase III SIERRA Clinical Trial For Iomab-B
6/12/2017
-
Actinium Names A New CEO, Effective Immediately
6/9/2017
-
Actinium Highlights Presence At Upcoming Society Of Nuclear Medicine And Molecular Imaging Annual Meeting
6/8/2017
-
Actinium To Host Webinar On June 12th To Update On Pivotal Phase III SIERRA Clinical Trial For Iomab-B
6/2/2017
-
Actinium Granted Orphan Designation From The EMA For Actimab-A
5/24/2017
-
Actinium Announces Appointment Of Hematology Expert Dr. Richard Stone Of The Dana-Farber Cancer Institute To Its Scientific Advisory Board
5/17/2017
-
Actinium Receives Clearance From Health Canada To Initiate Pivotal Phase III SIERRA Trial Of Iomab-B
5/10/2017
-
Actinium Announces Sponsorship Of The Acute Leukemia Forum 2017
4/19/2017
-
Actinium Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., To The Company’s Board Of Directors
3/28/2017
-
Actinium Announces Receipt Of Positive Scientific Advice From The EMA For Iomab-B
3/21/2017